Contents

Pro	st of examples		xi	
Lis	t of e	xample	s	xiii
1	Int	roduc	tion	1
	1.1		are Bayesian methods?	1
	1.2		do we mean by 'health-care evaluation'?	2
	1.3		esian approach to evaluation	3
	1.4		m of this book and the intended audience	3
	1.5	Structi	are of the book	4
2	Bas	sic Co	ncepts from Traditional Statistical Analysis	9
	2.1	Probab	pility	10
		2.1.1	What is probability?	10
		2.1.2	Odds and log-odds	12
		2.1.3	Bayes theorem for simple events	13
	2.2	Rando	m variables, parameters and likelihood	14
		2.2.1	Random variables and their distributions	14
		2.2.2	Expectation, variance, covariance and correlation	16
		2.2.3	Parametric distributions and conditional independence	17
		2.2.4	Likelihoods	18
	2.3	The normal distribution		
	2.4 Normal likelihoods		al likelihoods	22
		2.4.1	Normal approximations for binary data	23
		2.4.2	Normal likelihoods for survival data	27
		2.4.3	Normal likelihoods for count responses	30
		2.4.4	Normal likelihoods for continuous responses	31
	2.5	Classic	cal inference	31
	2.6	A cata	logue of useful distributions*	34
		2.6.1	Binomial and Bernoulli	34
		2.6.2	Poisson	35
		2.6.3	Beta	3€
		2.6.4	Uniform	38
		2.6.5	Gamma	39
		2.6.6	Root-inverse-gamma	40
		2.6.7	Half-normal	41

•	
V1	Contents

		2.6.8 Log-normal	42
		2.6.9 Student's t	43
		2.6.10 Bivariate normal	44
	2.7	Key points	46
	Exer	cises	46
3	An	Overview of the Bayesian Approach	49
	3.1	Subjectivity and context	49
	3.2	Bayes theorem for two hypotheses	51
	3.3	Comparing simple hypotheses: likelihood ratios and Bayes factors	54
	3.4	Exchangeability and parametric modelling*	56
	3.5	Bayes theorem for general quantities	57
	3.6	Bayesian analysis with binary data	57
		3.6.1 Binary data with a discrete prior distribution	58
		3.6.2 Conjugate analysis for binary data	59
	3.7	Bayesian analysis with normal distributions	62
	3.8	Point estimation, interval estimation and interval hypotheses	64
	3.9	The prior distribution	73
	3.10		74
	3.11	J J	75
	3.12		79
	3.13		80
		3.13.1 Predictions in the Bayesian framework	80
		3.13.2 Predictions for binary data*	81
	2.14	3.13.3 Predictions for normal data	83
		Decision-making	85
		Design Use of historical 1.4	90
		Use of historical data	90
		Multiplicity, exchangeability and hierarchical models	91 100
	3.10	Dealing with nuisance parameters* 3.18.1 Alternative methods for eliminating nuisance parameters*	100
		3.18.2 Profile likelihood in a hierarchical model*	100
	3 10	Computational issues	102
	3.17	3.19.1 Monte Carlo methods	102
		3.19.2 Markov chain Monte Carlo methods	105
		3.19.3 WinBUGS	107
	3.20	Schools of Bayesians	112
		A Bayesian checklist	113
		Further reading	115
	3.23	Key points	116
	Exerci		117
4	Con	nparison of Alternative Approaches to Inference	121
	4.1	A structure for alternative approaches	121
	4.2	Conventional statistical methods used in health-care evaluation	122
	4.3	The likelihood principle, sequential analysis and types of error	124
		4.3.1 The likelihood principle	124
		4.3.2 Sequential analysis	126
		4.3.3 Type I and Type II error	127
	4.4	P-values and Bayes factors*	127

			Contents	vii
		4.4.1	Criticism of P-values	127
		4.4.2	Bayes factors as an alternative to P-values: simple hypotheses	128
		4.4.3	Bayes factors as an alternative to P-values: composite hypotheses	130
		4.4.4	Bayes factors in preference studies	133
		4.4.5	Lindley's paradox	135
	4.5	Key po	•	136
	Exerc			136
5	Pri	or Dis	tributions	139
	5.1	Introdu	action	139
	5.2	Elicitat	ion of opinion: a brief review	140
		5.2.1	Background to elicitation	140
		5.2.2	Elicitation techniques	141
		5.2.3	Elicitation from multiple experts	142
	5.3		e of prior elicitation	147
	5.4		ary of external evidence*	148
	5.5		t priors	157
		5.5.1	'Non-informative' or 'reference' priors:	157
		5.5.2	'Sceptical' priors	158
		5.5.3	'Enthusiastic' priors	160
		5.5.4	Priors with a point mass at the null hypothesis	161
			('lump-and-smear' priors)*	161
	5.6		vity analysis and 'robust' priors	165
	5.7		chical priors	167
		5.7.1	The judgement of exchangeability The form for the random-effects distribution	167 168
		5.7.2	The prior for the standard deviation of the random effects*	168
	F 0	5.7.3	•	174
	5.8 5.9	Key po	cal criticism of priors	176
	Exerc		mits	177
6	Rai	ndomi	ised Controlled Trials	181
		7	and an	181
	6.1	Introd	a loss function: is a clinical trial for inference or decision?	182
	6.2		cation of null hypotheses	184
	6.3	Specific	and randomisation: a brief review	187
	6.4		Is randomisation necessary?	187
		6.4.1 6.4.2	When is it ethical to randomise?	187
	6.5		e size of non-sequential trials	189
	0.5	6.5.1	Alternative approaches to sample-size assessment	189
		6.5.2	'Classical power': hybrid classical-Bayesian methods	107
		0.5.2	assuming normality	193
		6.5.3	'Bayesian power'	194
		6.5.4	Adjusting formulae for different hypotheses	196
		6.5.5	Predictive distribution of power and necessary sample size	201
	6.6		oring of sequential trials	202
	0.0	6.6.1	Introduction	202
		6.6.2	Monitoring using the posterior distribution	204
		6.6.3	Monitoring using predictions: 'interim power'	211
		6.6.4	Monitoring using a formal loss function	220

viii	Contents

		6.6.5 Frequentist properties of sequential Bayesian methods6.6.6 Bayesian methods and data monitoring committees	221 222	
	6.7	The role of 'scepticism' in confirmatory studies	224	
	6.8	Multiplicity in randomised trials	227	
		6.8.1 Subset analysis	227	
		6.8.2 Multi-centre analysis	227	
		6.8.3 Cluster randomisation	227	
		6.8.4 Multiple endpoints and treatments	228	
	6.9	Using historical controls*	228	
	6.10		235	
	6.11	Trial designs other than two parallel groups	237	
		Other aspects of drug development	242	
		Further reading	244	
		Key points	245	
	Exerc	ises	247	
7	Obs	Observational Studies		
	7.1	Introduction	251	
	7.2	Alternative study designs	252	
	7.3	Explicit modelling of biases	253	
	7.4	Institutional comparisons	258	
	7.5	Key points	262	
	Exerc	ses	263	
8	Evic	lence Synthesis	267	
	8.1	Introduction	267	
	8.2	'Standard' meta-analysis	268	
		8.2.1 A Bayesian perspective	268	
		8.2.2 Some delicate issues in Bayesian meta-analysis	274	
		8.2.3 The relationship between treatment effect and underlying risk	278	
	8.3	Indirect comparison studies	282	
	8.4	Generalised evidence synthesis	285	
	8.5	Further reading	298	
	8.6	Key points	299	
	Exerci	ses	299	
9	Cost	-effectiveness, Policy-Making and Regulation	305	
	9.1	Introduction	305	
	9.2	Contexts	306	
	9.3	'Standard' cost-effectiveness analysis without uncertainty	308	
	9.4	'Two-stage' and integrated approaches to uncertainty in cost-effectiveness		
		modelling	310	
	9.5	Probabilistic analysis of sensitivity to uncertainty about parameters:		
		two-stage approach	312	
	9.6	Cost-effectiveness analyses of a single study: integrated approach	315	
	9.7	Levels of uncertainty in cost-effectiveness models	320	
	9.8	Complex cost-effectiveness models	322	
		9.8.1 Discrete-time, discrete-state Markov models	322	
		9.8.2 Micro-simulation in cost-effectiveness models	323	

		Contents	i x
		9.8.3 Micro-simulation and probabilistic sensitivity analysis	324
		9.8.4 Comprehensive decision modelling	328
	9.9	Simultaneous evidence synthesis and complex cost-effectiveness modelling	329
		9.9.1 Generalised meta-analysis of evidence	329
		9.9.2 Comparison of integrated Bayesian and two-stage approach	335
	9.10	Cost-effectiveness of carrying out research: payback models	335
		9.10.1 Research planning in the public sector	335
		9.10.2 Research planning in the pharmaceutical industry	336
		9.10.3 Value of information	337
	9.11	Decision theory in cost-effectiveness analysis, regulation and policy	341
	9.12	Regulation and health policy	343
		9.12.1 The regulatory context	343
		9.12.2 Regulation of pharmaceuticals	343
		9.12.3 Regulation of medical devices	344
	9.13	Conclusions	344
	9.14	Key points	345
	Exer	cises	345
10	Cor	nclusions and Implications for Future Research	349
	10.1	Introduction	349
		General advantages and problems of a Bayesian approach	349
		Future research and development	350
A	We	bsites and Software	353
		Mb. rise for ship head	353
	A.1	The site for this book	353
	A.2	Bayesian methods in health-care evaluation	354
	A.3	Bayesian software	355
	A.4	General Bayesian sites	333
Refe	rence	s	357
Inde	x		381